Megace

See also: Generic Megace ES

Megace is a brand name of megestrol, approved by the FDA in the following formulation(s):

MEGACE (megestrol acetate - suspension; oral)

• 
  Manufacturer: BRISTOL MYERS SQUIBB
  
  Approval date: September 10, 1993
  
  Strength(s): 40MG/ML ^[RLD][AB]

Has a generic version of Megace been approved?

A generic version of Megace has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Megace and have been approved by the FDA:

megestrol acetate suspension; oral

• 
  Manufacturer: APOTEX INC
  
  Approval date: February 16, 2006
  
  Strength(s): 40MG/ML ^[AB]


• 
  Manufacturer: PAR PHARM
  
  Approval date: July 25, 2001
  
  Strength(s): 40MG/ML ^[AB]


• 
  Manufacturer: ROXANE
  
  Approval date: February 15, 2002
  
  Strength(s): 40MG/ML ^[AB]


• 
  Manufacturer: TEVA PHARMS
  
  Approval date: May 5, 2003
  
  Strength(s): 40MG/ML ^[AB]


• 
  Manufacturer: WOCKHARDT
  
  Approval date: November 1, 2004
  
  Strength(s): 40MG/ML ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Megace. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Megestrol acetate formulation
  Patent 5,338,732
  Issued: August 16, 1994
  Inventor(s): Atzinger; Anne E. & Bequette; Robert J. & Davis; Robert E.
  Assignee(s): Bristol-Myers Squibb Company
  The present invention relates to a novel oral pharmaceutical composition of micronized megestrol acetate at a concentration of 15 to 150 mg/mL comprising polysorbate at a concentration of 0.005% to 0.015% weight/volume and polyethylene glycol at a concentration of 5-30% weight/volume which composition forms a stable flocculated suspension in water. The invention further comprises the micronized megestrol acetate formulation described above with added preservatives, buffers, sweeteners and flavoring agents.
  
  Patent expiration dates:
  
  
  • August 16, 2011
    
  
  

See also...

• Megace Suspension Consumer Information (Wolters Kluwer)
• Megace Consumer Information (Cerner Multum)
• Megace AHFS DI Monographs (ASHP)
• Megestrol Consumer Information (Wolters Kluwer)
• Megestrol Suspension Consumer Information (Wolters Kluwer)
• Megestrol Consumer Information (Cerner Multum)
• Megestrol Acetate AHFS DI Monographs (ASHP)